Market Intelligence, Clinical Progress, and High-Purity Reagents for Osteoarthritis and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MMP13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MMP13 Recombinant Protein (Pro-form & Active) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic activity assays and SPR. |
View MMP13 Products |
| Gene Delivery | MMP13 Promise-ORF / Lentivirus Full-length ORF for stable cell lines, enabling cell-based cleavage assays. |
View MMP13 Products |
| Benchmark Ab | Anti-MMP13 Recombinant Antibody High-affinity positive control for ELISA, Western Blot, and IHC. |
View MMP13 Products |
| Validator | MMP13 siRNA Set Target-specific knockdown verification in primary chondrocytes or cancer cell lines. |
View MMP13 Products |
| Related Target A | MMP1 Critical counter-screening target. Off-target inhibition of MMP1 causes musculoskeletal syndrome (MSS). |
View MMP1 Products |
| Related Target B | MMP8 Homologous collagenase. Essential for selectivity profiling of MMP13 inhibitors. |
View MMP8 Products |
| Related Target C | MMP9 Gelatinase B. Often co-expressed in inflammatory joints and tumor microenvironments. |
View MMP9 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| MMP Subfamily Off-target Screening | A complete panel of homologous MMP proteins (MMP1, MMP2, MMP8, MMP9, MMP14) strictly verified by mass spectrometry and SDS-PAGE. |
| Zymogen vs. Active Enzyme Assay | Both Pro-form (inactive) and APMA-activated (active) MMP13 proteins available with documented theoretical MW and high purity. |
| Lack of Validated Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| In Vitro Knockdown Validation | Sequence-specific siRNA pools provided with guaranteed target gene knockdown efficiency. |
Live MMP13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MMP13 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum metalloproteinase inhibitors to highly selective allosteric small molecules and monoclonal antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting cartilage-specific delivery systems and combination regimens to treat osteoarthritis (OA) and prevent cartilage degradation without systemic musculoskeletal side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Galapagos, Servier, Pfizer | Osteoarthritis (DMOAD) | Selectivity Assay (Need a panel of active MMP1, MMP8, MMP14 mutant/WT proteins) |
| Monoclonal Antibody | Academic/Biotech consortia | Oncology (TME remodeling), RA | Epitope mapping & cross-species reactivity (Need Human/Mouse/Rat MMP13) |
| siRNA / Gene Therapy | Local delivery biotechs | Joint Cartilage Degeneration | In vitro knockdown verification (Need high-specificity siRNA & Lentivirus) |